Clinical Trial

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Study acronym: PREOPANC-5
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment with chemotherapy (mFOLFIRINOX), immunotherapy (pembrolizumab and stereotactic radiotherapy, followed by adjuvant surgery and chemotherapy and immunotherapy, improves survival in patients with (borderline) resectabel pancreatic cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-22; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2025-01-16
Trial Details
NCT Number NCT06384560
Lead Sponsor Amsterdam UMC, location VUmc
Collaborators: Maastricht University Medical Center, Erasmus Medical Center, St. Antonius Hospital
Conditions Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Enrollment 66 participants
Start Date 2024-09-23
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-13